Search ↗

Comparison

Thymosin Alpha-1 vs Zn-Thymulin

Both are thymic & immune, so the meaningful differences are in kinetics, evidence and regulatory status.

On published evidence alone, Thymosin Alpha-1 is the better documented of the two (clinical trials). That is a statement about the state of the literature, not a recommendation.

Thymosin Alpha-1 Zn-Thymulin
Class Thymic & immune Thymic & immune
Evidence Clinical trials Preliminary human
Human trials ~40 ~2
Half-life ~2 hours ~30 minutes
Reported range 1.6-3.2 mg 100-200 mcg
Frequency 2x weekly Daily topical application
Routes Subcutaneous Topical, Subcutaneous
FDA approved No No
Research use only Yes Yes
Banned in sport No No
Studied for Chronic hepatitis B and C, Immune modulation, Vaccine adjuvant research, Sepsis research Immune modulation research, Hair loss research
Reported side effects Injection-site erythema, Transient fatigue, Mild flu-like symptoms Scalp irritation, Injection-site reactions

Thymosin Alpha-1

Thymosin alpha-1 is a 28-residue peptide originally isolated from thymic tissue. It acts largely through Toll-like receptor signalling on dendritic cells, promoting maturation of T cells and enhancing Th1 responses, natural killer cell activity and antigen presentation. Unlike most compounds on this site it has a substantial approved clinical history outside the US, including as an adjuvant in hepatitis B and C and in sepsis research.

Zn-Thymulin

Thymulin is a nonapeptide produced by thymic epithelial cells that is biologically active only when bound to zinc, which is why zinc status directly governs its function. It influences T-cell differentiation and has documented anti-inflammatory and antinociceptive activity in animal models. Separately, topical thymulin products are marketed for hair loss, which accounts for most current commercial interest, but a hair-growth benefit has not been established in humans.

Thymosin Alpha-1 vs Zn-Thymulin: common questions

What is the difference between Thymosin Alpha-1 and Zn-Thymulin?

Both are thymic & immune. Thymosin Alpha-1: A thymic immunomodulatory peptide approved in more than 30 countries for hepatitis B and C, though not in the United States. Zn-Thymulin: A zinc-dependent thymic nonapeptide, of interest for immune signalling and marketed as a topical hair-loss product, though a hair benefit is not established in humans.

Which has stronger evidence, Thymosin Alpha-1 or Zn-Thymulin?

Thymosin Alpha-1 has the stronger evidence base (clinical trials, about 40 human studies) compared with Zn-Thymulin (preliminary human).

Are Thymosin Alpha-1 and Zn-Thymulin FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 16130571) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. CAS Registry Number 62304-98-7 ↗ · chemical identity

Published literature

  1. Hannappel E. beta-Thymosins.Ann N Y Acad Sci 2007.PubMed 17468232 · doi:10.1196/annals.1415.018
  2. Ancell CD, Phipps J, Young L. Thymosin alpha-1.Am J Health Syst Pharm 2001.PubMed 11381492 · doi:10.1093/ajhp/58.10.886
  3. Hadden JW. T-cell adjuvants.Int J Immunopharmacol 1994.PubMed 7806429 · doi:10.1016/0192-0561(94)90090-6
  4. Hadden JW. Thymic endocrinology.Ann N Y Acad Sci 1998.PubMed 9629262 · doi:10.1111/j.1749-6632.1998.tb09574.x
  5. Rubin BK. Unmet needs in cystic fibrosis.Expert Opin Biol Ther 2018.PubMed 30063865 · doi:10.1080/14712598.2018.1484101
  6. Hoch K, Volk DE. Structures of Thymosin Proteins.Vitam Horm 2016.PubMed 27450728 · doi:10.1016/bs.vh.2016.04.009
  7. Gu B, Zhou Y, Nie Y, et al.. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Front Cell Infect Microbiol 2025.PubMed 40969554 · doi:10.3389/fcimb.2025.1673959
  8. Simonova MA, Ivanov I, Shoshina NS, et al.. Aging and Thymosin Alpha-1.Int J Mol Sci 2025.PubMed 41373628 · doi:10.3390/ijms262311470
  9. Hadden JW. Immunodeficiency and cancer: prospects for correction.Int Immunopharmacol 2003.PubMed 12860163 · doi:10.1016/S1567-5769(03)00060-2
  10. Licastro F, Mocchegiani E, Masi M, et al.. Modulation of the neuroendocrine system and immune functions by zinc supplementation in children with Down's syndrome.J Trace Elem Electrolytes Health Dis 1993.PubMed 8019155

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.